A panel of biologically contained orthoebolaviruses for the screening of broad-spectrum antivirals
Verlinden, J.; Stroobants, J.; Nonay, J. S.; Willems, C.; Govaerts, K.; Van Holm, B.; Chiu, W.; Schepers, J.; Francken, T.; Lemmens, V.; Vermeire, K.; Vanmechelen, B.
Show abstract
Filoviruses, particularly those of the Orthoebolavirus genus, pose ongoing public health threats due to their increasing frequency and geographic spread. However, research has been impeded by the biosafety level 4 classification of filoviruses. We previously reported the generation of biologically contained Ebola, Marburg and Sudan virus as lower biosafety level-compatible filovirus systems. In the present study, we expanded this repertoire to include biologically contained Tai Forest, Bundibugyo and Reston virus, thereby creating a near-complete toolkit for currently recognized human-relevant orthoebolaviruses. VP30-deficient viruses were generated with matching VP30 expressing cell lines. More specifically, we developed and optimized a dual-reporter system in VeroE6, Huh-7 and A549 cells, combining a virus-encoded enhanced green fluorescent protein reporter as readout for viral replication with a stably cellular-expressed nuclear mCherry marker for cytotoxicity assessment. Next, we screened two repurposing-oriented compound libraries comprising 640 small molecules against Tai Forest, Bundibugyo and Sudan virus, and subsequently cross-validated against Reston and Ebola virus. This approach identified multiple candidates with broad-spectrum activity across orthoebolaviruses, while also revealing virus-specific antivirals, with robust activity observed in both primate- and human-derived cell lines. Together, this work establishes a versatile and experimentally tractable lower biosafety level-compatible platform for the study of human-relevant orthoebolaviruses and the systematic discovery of broad-spectrum antiviral countermeasures against filoviruses.
Matching journals
The top 10 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Bemnifosbuvir and remdesivir inhibit tick-borne encephalitis virus infection in complementary in vitro and ex vivo disease models 94%
- Combinations of approved oral nucleoside analogues confer potent suppression of alphaviruses in vitro and in vivo 94%
- Identification of novel Ebola virus inhibitors using biologically contained virus 93%
Similar papers in this journal
- Oral drug repositioning candidates and synergistic remdesivir combinations for the prophylaxis and treatment of COVID-19 93%
- Emergence of transmissible SARS-CoV-2 variants with decreased sensitivity to antivirals in immunocompromised patients with persistent infections 92%
- Oral dosing of the nucleoside analog obeldesivir is efficacious against RSV infection in African green monkeys 91%
Similar papers in this journal
- Screening a library of FDA-approved and bioactive compounds for antiviral activity against SARS-CoV-2 92%
- Immunogenicity and protective efficacy of a highly thermotolerant, trimeric SARS-CoV-2 receptor binding domain derivative 92%
- Legacy 4(1H)-quinolone scaffolds activity against acute and chronic Toxoplasma gondii infection 92%
Similar papers in this journal
- Discovery of a potent anti-Zika virus benzamide series targeting the viral protein NS4B 95%
- A guanidine-based coronavirus replication inhibitor which targets the nsp15 endoribonuclease and selects for interferon-susceptible mutant viruses 93%
- NRF2 activators inhibit influenza A virus replication by interfering with nucleo-cytoplasmic export of viral RNPs in an NRF2-independent manner 93%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.